Reorganization enhances organizational focus on strategic priorities Clinical update on DLBCL patients in Phase 2B VITALIZE trial to be provided in September Appointment of Dr. Saman Maleki to Board of Directors Brittany Davison promoted to Chief Acco
WVVA is one of the first in the nation to become stewards in regenerative practices and sustainable travel CORVALLIS, Ore.--(BUSINESS WIRE)--The Willamette Valley Visitors Association (WVVA) recently became the first early adopter to join The Transformat
VICTORIA, British Columbia--(BUSINESS WIRE)--$IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), announced today that its subsidiary, Talem Therapeutics LLC (“Talem”), has shared positive results o
One of the larger propagators in the Netherlands, Westlandse Plantenkwekerij, implemented a hybrid lighting approach using Fluence’s VYPR fixtures, resulting in increased quality and control over environmental factors AUSTIN, Texas & ROTTERDAM, Netherl
Structural HYFTs fully indexed and integrated in structure-function workflow LENSai® data management platform successfully launches hyper-scalable solution for partner access, integrating multiple data layers at once Company shares BioStrand case s
Former Novartis and AstraZeneca industry veteran Ruben Tommasi joins Dunad Therapeutics leadership team CAMBRIDGE, England--(BUSINESS WIRE)--Dunad Therapeutics, a biopharmaceutical company developing small molecule covalent therapies based on novel insig
CAD 10M financing arrangement with Tetra Bio-Pharma (TBP) NASSAU, Bahamas--(BUSINESS WIRE)--ABO, a family office founded by Pierre Vannineuse and a pioneer in alternative finance worldwide, is proud to support Tetra Bio-Pharma’s growth initiatives with
New ultra-low powered cellular router solution powered by AirLink OS enables next-generation networking capabilities for industry 4.0 applications VANCOUVER, British Columbia--(BUSINESS WIRE)--Sierra Wireless (NASDAQ: SWIR) (TSX: SW), a world leading IoT
Unmatched solution delivers corrective actions, regulatory expertise and supplier engagement to enable complex manufacturers to stay ahead of evolving ESG standards and regulations OTTAWA, Ontario--(BUSINESS WIRE)--#AssentESG--Assent Inc. (Assent), a lea
-- Enrolling in ACTION-1 study, a Phase 1b/3 trial of RYZ101, for treatment of neuroendocrine tumors -- FDA clearance of second Investigational New Drug Application for RYZ101 in small cell lung cancer -- RYZ101 positioned to be the first approved Acti
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.